Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection

Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats

(2011) Derek A Persons et al.   MOLECULAR THERAPY

10-Year stability of clinical-grade serum-free γ-retroviral vector-containing medium

(2010) F Herbst et al.   GENE THERAPY

Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application

(2010) Otto-Wilhelm Merten et al.   HUMAN GENE THERAPY

Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection

(2009) R. E. Throm et al.   BLOOD

A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration

(2009) R Loew et al.   GENE THERAPY

Transient Transfection Methods for Clinical Adeno-Associated Viral Vector Production

(2009) J. Fraser Wright   HUMAN GENE THERAPY

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients

(2008) Steven J. Howe et al.   JOURNAL OF CLINICAL INVESTIGATION

Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined Immunodeficiency

(2008) Susannah I Thornhill et al.   MOLECULAR THERAPY

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

(2008) Daniela Zychlinski et al.   MOLECULAR THERAPY